WENGEL, KATHRYN E
EVP, Chief TO and Risk Officer
- Shares
- 10.00K
- % company
- <0.01%
- Price
- $115.67
- Value
- $1,156,700
Filed Jun 11, 2026
Methodology published · Market data, model notes, and corrections process are public · Data policy · Corrections policy
NYSE · Healthcare · Holders
Johnson & Johnson (JNJ) Institutional Ownership & Insider Trading History
Recent insider purchases and sales for JNJ from Form 4 filings. Institutional holdings surface here when ownership sources publish.
Section freshness
Price Jun 23, 4:00 PM EDT · Statements Mar 30, 8:00 PM EDT
Source timingDetailsHide
Data freshness
Prices update fastest. Fundamentals, analyst data, and news update on their own schedules, so check these timestamps before comparing signals.
Price time means the latest available trade or regular-market close. Other times show when that section was checked or published.
PriceLive
Last traded •
Source: Market data provider
Fundamentalsevery 1 hr
Provider checked •
Source: Market data provider
Analystevery 1 hr
Provider checked •
Source: Market data provider
Newsevery 15 min
Latest item •
Source: Market data provider
Ownership read
JNJ insider sentiment: Mixed, buy-heavy.
60 sales and 60 purchases appear in the recent Form 4 filings. Use the filters below to separate real buying and selling from option exercises, gifts, awards, and tax withholding.
Insider flow
JNJ
Purchases649.26K
Sales453.27K
Directional bars ignore awards, gifts, conversions, and tax withholding rows.
Top holder
—
Institutional data pending
Insider stance
Mixed, buy-heavy
$55.22M sold / $24.28M bought
Latest filing
Jun 11, 2026
Most recent holder or insider filing date
Filings shown
120
0 holder / 120 insider
- Holder rows
- Pending
- Market data source
- Latest filing
- Jun 11, 2026
- Most recent holder or insider filing date
- Increased / initiated
- Pending
- 0 decreased
- Insider rows
- 120
- Market data source
Recent insider transactions
Johnson & Johnson (JNJ) Form 4 filings
Action codes are translated so open-market buys and sales are separate from awards, gifts, conversions, and tax withholding.
WENGEL, KATHRYN E
EVP, Chief TO and Risk Officer
- Shares
- 10.00K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Jun 11, 2026
WENGEL, KATHRYN E
EVP, Chief TO and Risk Officer
- Shares
- 10.00K
- % company
- <0.01%
- Price
- $241.15
- Value
- $2,411,500
Filed Jun 11, 2026
HEWSON, MARILLYN A
Director
- Shares
- 215
- % company
- <0.01%
- Price
- $232.79
- Value
- $50,000
Filed Jun 9, 2026
PINTO, DANIEL E
Director
- Shares
- 134
- % company
- <0.01%
- Price
- $232.79
- Value
- $31,250
Filed Jun 9, 2026
WOODS, EUGENE A.
Director
- Shares
- 161
- % company
- <0.01%
- Price
- $232.79
- Value
- $37,500
Filed Jun 9, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 11.00K
- % company
- <0.01%
- Price
- $229.85
- Value
- $2,528,810
Filed May 1, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 25.25K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed May 1, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 25.25K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed May 1, 2026
JOLY, HUBERT
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
WOODS, EUGENE A.
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
WEST, NADJA
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
WEINBERGER, MARK A
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
PINTO, DANIEL E
Director
- Shares
- 1.71K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
MORIKIS, JOHN G
Director
- Shares
- 1.54K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
MCCLELLAN, MARK B.
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
JOHNSON, PAULA A
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
HEWSON, MARILLYN A
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
DOUDNA, JENNIFER A
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
BECKERLE, MARY C
Director
- Shares
- 975
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Apr 23, 2026
HEWSON, MARILLYN A
Director
- Shares
- 206
- % company
- <0.01%
- Price
- $242.14
- Value
- $50,000
Filed Mar 10, 2026
PINTO, DANIEL E
Director
- Shares
- 129
- % company
- <0.01%
- Price
- $242.14
- Value
- $31,250
Filed Mar 10, 2026
WOODS, EUGENE A.
Director
- Shares
- 155
- % company
- <0.01%
- Price
- $242.14
- Value
- $37,500
Filed Mar 10, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 4.08K
- % company
- <0.01%
- Price
- $247.87
- Value
- $1,010,070
Filed Feb 27, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 4.08K
- % company
- <0.01%
- Price
- $115.67
- Value
- $471,355
Filed Feb 27, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 4.08K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 27, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 1.32K
- % company
- <0.01%
- Price
- $245.66
- Value
- $324,763
Filed Feb 20, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 9.00K
- % company
- <0.01%
- Price
- $129.51
- Value
- $1,165,331
Filed Feb 18, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 13.63K
- % company
- <0.01%
- Price
- $115.67
- Value
- $1,576,004
Filed Feb 18, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 9.00K
- % company
- <0.01%
- Price
- $244.53
- Value
- $2,200,281
Filed Feb 18, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 13.63K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 18, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 9.00K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 18, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 13.63K
- % company
- <0.01%
- Price
- $244.20
- Value
- $3,327,225
Filed Feb 18, 2026
SWANSON, JAMES D.
EVP, CIO
- Shares
- 20.52K
- % company
- <0.01%
- Price
- $164.62
- Value
- $3,378,167
Filed Feb 17, 2026
SWANSON, JAMES D.
EVP, CIO
- Shares
- 20.52K
- % company
- <0.01%
- Price
- $242.70
- Value
- $4,980,447
Filed Feb 17, 2026
SWANSON, JAMES D.
EVP, CIO
- Shares
- 20.52K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 19.24K
- % company
- <0.01%
- Price
- $115.67
- Value
- $2,225,606
Filed Feb 17, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 6.20K
- % company
- <0.01%
- Price
- $243.39
- Value
- $1,508,288
Filed Feb 17, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 29.93K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 33.39K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 19.24K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 12.07K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 24.96K
- % company
- <0.01%
- Price
- $242.68
- Value
- $6,057,535
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 33.39K
- % company
- <0.01%
- Price
- $242.75
- Value
- $8,104,452
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 33.39K
- % company
- <0.01%
- Price
- $131.94
- Value
- $4,404,949
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 12.07K
- % company
- <0.01%
- Price
- $242.87
- Value
- $2,930,469
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 12.07K
- % company
- <0.01%
- Price
- $129.51
- Value
- $1,562,668
Filed Feb 17, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 19.24K
- % company
- <0.01%
- Price
- $242.99
- Value
- $4,675,371
Filed Feb 17, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 21.72K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 17, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 2.28K
- % company
- <0.01%
- Price
- $243.00
- Value
- $554,769
Filed Feb 17, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 29.93K
- % company
- <0.01%
- Price
- $243.00
- Value
- $7,272,261
Filed Feb 17, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 29.93K
- % company
- <0.01%
- Price
- $156.15
- Value
- $4,673,101
Filed Feb 17, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 21.72K
- % company
- <0.01%
- Price
- $243.00
- Value
- $5,278,203
Filed Feb 17, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 21.72K
- % company
- <0.01%
- Price
- $157.92
- Value
- $3,430,180
Filed Feb 17, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 344
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 339
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 94
- % company
- <0.01%
- Price
- $243.45
- Value
- $22,884
Filed Feb 15, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 95
- % company
- <0.01%
- Price
- $243.45
- Value
- $23,128
Filed Feb 15, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 339
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 344
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 4.87K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DECKER, ROBERT J
VP Corporate Controller
- Shares
- 700
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 1.35K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 385
- % company
- <0.01%
- Price
- $243.45
- Value
- $93,728
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 1.85K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 528
- % company
- <0.01%
- Price
- $243.45
- Value
- $128,542
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 1.35K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 1.85K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 49.38K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
REED, JOHN C
EVP, Innovative Medicine, R&D
- Shares
- 3.55K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
FORMINARD, ELIZABETH
EVP, Chief Legal Officer
- Shares
- 961
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 1.59K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 816
- % company
- <0.01%
- Price
- $243.45
- Value
- $198,655
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 1.85K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 945
- % company
- <0.01%
- Price
- $243.45
- Value
- $230,060
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 1.59K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 1.85K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 54.87K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 1.03K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 14.40K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 526
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 492
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 270
- % company
- <0.01%
- Price
- $243.45
- Value
- $65,732
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 526
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 252
- % company
- <0.01%
- Price
- $243.45
- Value
- $61,349
Filed Feb 15, 2026
BROADHURST, VANESSA
EVP, Global Corp Affairs
- Shares
- 492
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
TAUBERT, JENNIFER L
EVP, WWC. Innovative Medicine
- Shares
- 3.94K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 1.03K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 15
- % company
- <0.01%
- Price
- $243.45
- Value
- $3,652
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 1.03K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
WENGEL, KATHRYN E
EVP, Chief TO and Risk Officer
- Shares
- 16.95K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
WENGEL, KATHRYN E
EVP, Chief TO and Risk Officer
- Shares
- 635
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
WENGEL, KATHRYN E
EVP, Chief TO and Risk Officer
- Shares
- 606
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 131.73K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 4.50K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 3.68K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 9.46K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 1.96K
- % company
- <0.01%
- Price
- $243.45
- Value
- $477,162
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 4.50K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 1.60K
- % company
- <0.01%
- Price
- $243.45
- Value
- $390,007
Filed Feb 15, 2026
DUATO, JOAQUIN
Director, CEO and Chairman of the Board
- Shares
- 3.68K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 1.97K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 1.88K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 53.79K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
WOLK, JOSEPH J
Exec VP, CFO
- Shares
- 3.86K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 2.55K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 35.49K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 1.03K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 1.03K
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
SCHMID, TIMOTHY
EVP, WW Chair, MedTech
- Shares
- 448
- % company
- <0.01%
- Price
- $243.45
- Value
- $109,066
Filed Feb 15, 2026
MULHOLLAND, KRISTEN
EVP, Chief HR Officer
- Shares
- 575
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
MULHOLLAND, KRISTEN
EVP, Chief HR Officer
- Shares
- 419
- % company
- <0.01%
- Price
- Not reported
- Value
- Not reported
Filed Feb 15, 2026
| # | Insider | % company | Action | Shares | Price | Value | Filing date |
|---|---|---|---|---|---|---|---|
| 1 | WENGEL, KATHRYN E EVP, Chief TO and Risk Officer | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 10.00K | $115.67 | $1,156,700 | Jun 11, 2026 |
| 2 | WENGEL, KATHRYN E EVP, Chief TO and Risk Officer | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 10.00K | Not reported | Not reported | Jun 11, 2026 |
| 3 | WENGEL, KATHRYN E EVP, Chief TO and Risk Officer | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 10.00K | $241.15 | $2,411,500 | Jun 11, 2026 |
| 4 | HEWSON, MARILLYN A Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 215 | $232.79 | $50,000 | Jun 9, 2026 |
| 5 | PINTO, DANIEL E Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 134 | $232.79 | $31,250 | Jun 9, 2026 |
| 6 | WOODS, EUGENE A. Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 161 | $232.79 | $37,500 | Jun 9, 2026 |
| 7 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 11.00K | $229.85 | $2,528,810 | May 1, 2026 |
| 8 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 25.25K | Not reported | Not reported | May 1, 2026 |
| 9 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 25.25K | Not reported | Not reported | May 1, 2026 |
| 10 | JOLY, HUBERT Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 11 | WOODS, EUGENE A. Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 12 | WEST, NADJA Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 13 | WEINBERGER, MARK A Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 14 | PINTO, DANIEL E Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.71K | Not reported | Not reported | Apr 23, 2026 |
| 15 | MORIKIS, JOHN G Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.54K | Not reported | Not reported | Apr 23, 2026 |
| 16 | MCCLELLAN, MARK B. Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 17 | JOHNSON, PAULA A Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 18 | HEWSON, MARILLYN A Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 19 | DOUDNA, JENNIFER A Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 20 | BECKERLE, MARY C Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 975 | Not reported | Not reported | Apr 23, 2026 |
| 21 | HEWSON, MARILLYN A Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 206 | $242.14 | $50,000 | Mar 10, 2026 |
| 22 | PINTO, DANIEL E Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 129 | $242.14 | $31,250 | Mar 10, 2026 |
| 23 | WOODS, EUGENE A. Director | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 155 | $242.14 | $37,500 | Mar 10, 2026 |
| 24 | DECKER, ROBERT J VP Corporate Controller | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 4.08K | $247.87 | $1,010,070 | Feb 27, 2026 |
| 25 | DECKER, ROBERT J VP Corporate Controller | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 4.08K | $115.67 | $471,355 | Feb 27, 2026 |
| 26 | DECKER, ROBERT J VP Corporate Controller | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 4.08K | Not reported | Not reported | Feb 27, 2026 |
| 27 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.32K | $245.66 | $324,763 | Feb 20, 2026 |
| 28 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 9.00K | $129.51 | $1,165,331 | Feb 18, 2026 |
| 29 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 13.63K | $115.67 | $1,576,004 | Feb 18, 2026 |
| 30 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 9.00K | $244.53 | $2,200,281 | Feb 18, 2026 |
| 31 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 13.63K | Not reported | Not reported | Feb 18, 2026 |
| 32 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 9.00K | Not reported | Not reported | Feb 18, 2026 |
| 33 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 13.63K | $244.20 | $3,327,225 | Feb 18, 2026 |
| 34 | SWANSON, JAMES D. EVP, CIO | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 20.52K | $164.62 | $3,378,167 | Feb 17, 2026 |
| 35 | SWANSON, JAMES D. EVP, CIO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 20.52K | $242.70 | $4,980,447 | Feb 17, 2026 |
| 36 | SWANSON, JAMES D. EVP, CIO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 20.52K | Not reported | Not reported | Feb 17, 2026 |
| 37 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 19.24K | $115.67 | $2,225,606 | Feb 17, 2026 |
| 38 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 6.20K | $243.39 | $1,508,288 | Feb 17, 2026 |
| 39 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 29.93K | Not reported | Not reported | Feb 17, 2026 |
| 40 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 33.39K | Not reported | Not reported | Feb 17, 2026 |
| 41 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 19.24K | Not reported | Not reported | Feb 17, 2026 |
| 42 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 12.07K | Not reported | Not reported | Feb 17, 2026 |
| 43 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 24.96K | $242.68 | $6,057,535 | Feb 17, 2026 |
| 44 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 33.39K | $242.75 | $8,104,452 | Feb 17, 2026 |
| 45 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 33.39K | $131.94 | $4,404,949 | Feb 17, 2026 |
| 46 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 12.07K | $242.87 | $2,930,469 | Feb 17, 2026 |
| 47 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 12.07K | $129.51 | $1,562,668 | Feb 17, 2026 |
| 48 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 19.24K | $242.99 | $4,675,371 | Feb 17, 2026 |
| 49 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 21.72K | Not reported | Not reported | Feb 17, 2026 |
| 50 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 2.28K | $243.00 | $554,769 | Feb 17, 2026 |
| 51 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 29.93K | $243.00 | $7,272,261 | Feb 17, 2026 |
| 52 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 29.93K | $156.15 | $4,673,101 | Feb 17, 2026 |
| 53 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 21.72K | $243.00 | $5,278,203 | Feb 17, 2026 |
| 54 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 21.72K | $157.92 | $3,430,180 | Feb 17, 2026 |
| 55 | DECKER, ROBERT J VP Corporate Controller | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 344 | Not reported | Not reported | Feb 15, 2026 |
| 56 | DECKER, ROBERT J VP Corporate Controller | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 339 | Not reported | Not reported | Feb 15, 2026 |
| 57 | DECKER, ROBERT J VP Corporate Controller | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 94 | $243.45 | $22,884 | Feb 15, 2026 |
| 58 | DECKER, ROBERT J VP Corporate Controller | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 95 | $243.45 | $23,128 | Feb 15, 2026 |
| 59 | DECKER, ROBERT J VP Corporate Controller | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 339 | Not reported | Not reported | Feb 15, 2026 |
| 60 | DECKER, ROBERT J VP Corporate Controller | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 344 | Not reported | Not reported | Feb 15, 2026 |
| 61 | DECKER, ROBERT J VP Corporate Controller | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 4.87K | Not reported | Not reported | Feb 15, 2026 |
| 62 | DECKER, ROBERT J VP Corporate Controller | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 700 | Not reported | Not reported | Feb 15, 2026 |
| 63 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.35K | Not reported | Not reported | Feb 15, 2026 |
| 64 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 385 | $243.45 | $93,728 | Feb 15, 2026 |
| 65 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.85K | Not reported | Not reported | Feb 15, 2026 |
| 66 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 528 | $243.45 | $128,542 | Feb 15, 2026 |
| 67 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.35K | Not reported | Not reported | Feb 15, 2026 |
| 68 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.85K | Not reported | Not reported | Feb 15, 2026 |
| 69 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 49.38K | Not reported | Not reported | Feb 15, 2026 |
| 70 | REED, JOHN C EVP, Innovative Medicine, R&D | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 3.55K | Not reported | Not reported | Feb 15, 2026 |
| 71 | FORMINARD, ELIZABETH EVP, Chief Legal Officer | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 961 | Not reported | Not reported | Feb 15, 2026 |
| 72 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.59K | Not reported | Not reported | Feb 15, 2026 |
| 73 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 816 | $243.45 | $198,655 | Feb 15, 2026 |
| 74 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.85K | Not reported | Not reported | Feb 15, 2026 |
| 75 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 945 | $243.45 | $230,060 | Feb 15, 2026 |
| 76 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.59K | Not reported | Not reported | Feb 15, 2026 |
| 77 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.85K | Not reported | Not reported | Feb 15, 2026 |
| 78 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 54.87K | Not reported | Not reported | Feb 15, 2026 |
| 79 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.03K | Not reported | Not reported | Feb 15, 2026 |
| 80 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 14.40K | Not reported | Not reported | Feb 15, 2026 |
| 81 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 526 | Not reported | Not reported | Feb 15, 2026 |
| 82 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 492 | Not reported | Not reported | Feb 15, 2026 |
| 83 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 270 | $243.45 | $65,732 | Feb 15, 2026 |
| 84 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 526 | Not reported | Not reported | Feb 15, 2026 |
| 85 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 252 | $243.45 | $61,349 | Feb 15, 2026 |
| 86 | BROADHURST, VANESSA EVP, Global Corp Affairs | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 492 | Not reported | Not reported | Feb 15, 2026 |
| 87 | TAUBERT, JENNIFER L EVP, WWC. Innovative Medicine | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 3.94K | Not reported | Not reported | Feb 15, 2026 |
| 88 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.03K | Not reported | Not reported | Feb 15, 2026 |
| 89 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 15 | $243.45 | $3,652 | Feb 15, 2026 |
| 90 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 1.03K | Not reported | Not reported | Feb 15, 2026 |
| 91 | WENGEL, KATHRYN E EVP, Chief TO and Risk Officer | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 16.95K | Not reported | Not reported | Feb 15, 2026 |
| 92 | WENGEL, KATHRYN E EVP, Chief TO and Risk Officer | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 635 | Not reported | Not reported | Feb 15, 2026 |
| 93 | WENGEL, KATHRYN E EVP, Chief TO and Risk Officer | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 606 | Not reported | Not reported | Feb 15, 2026 |
| 94 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 131.73K | Not reported | Not reported | Feb 15, 2026 |
| 95 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 4.50K | Not reported | Not reported | Feb 15, 2026 |
| 96 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 3.68K | Not reported | Not reported | Feb 15, 2026 |
| 97 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 9.46K | Not reported | Not reported | Feb 15, 2026 |
| 98 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.96K | $243.45 | $477,162 | Feb 15, 2026 |
| 99 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 4.50K | Not reported | Not reported | Feb 15, 2026 |
| 100 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.60K | $243.45 | $390,007 | Feb 15, 2026 |
| 101 | DUATO, JOAQUIN Director, CEO and Chairman of the Board | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 3.68K | Not reported | Not reported | Feb 15, 2026 |
| 102 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.97K | Not reported | Not reported | Feb 15, 2026 |
| 103 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.88K | Not reported | Not reported | Feb 15, 2026 |
| 104 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 53.79K | Not reported | Not reported | Feb 15, 2026 |
| 105 | WOLK, JOSEPH J Exec VP, CFO | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 3.86K | Not reported | Not reported | Feb 15, 2026 |
| 106 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 2.55K | Not reported | Not reported | Feb 15, 2026 |
| 107 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | PurchaseOpen-market or direct purchase reported on Form 4. | 35.49K | Not reported | Not reported | Feb 15, 2026 |
| 108 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.03K | Not reported | Not reported | Feb 15, 2026 |
| 109 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 1.03K | Not reported | Not reported | Feb 15, 2026 |
| 110 | SCHMID, TIMOTHY EVP, WW Chair, MedTech | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 448 | $243.45 | $109,066 | Feb 15, 2026 |
| 111 | MULHOLLAND, KRISTEN EVP, Chief HR Officer | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 575 | Not reported | Not reported | Feb 15, 2026 |
| 112 | MULHOLLAND, KRISTEN EVP, Chief HR Officer | <0.01% | SaleOpen-market or direct sale reported on Form 4. | 419 | Not reported | Not reported | Feb 15, 2026 |
Showing 112 of 120 matching Form 4 rows. Percent of company uses current shares outstanding when available.Load more insiders
Frequently asked
Common questions.
Who are the largest JNJ shareholders?
Johnson & Johnson (JNJ) institutional holders are ranked by reported share count when ownership data publishes filing rows.
What is institutional ownership of JNJ?
Johnson & Johnson (JNJ) institutional ownership appears when filing-based market data returns holder rows. TECHi does not fill unavailable ownership fields with placeholder shareholders.
Where can I see Johnson & Johnson insider transactions?
Johnson & Johnson (JNJ) has 120 Form 4 insider transactions on file, most recently on Jun 11, 2026, separated into purchases, sales, option exercises, awards, gifts, and tax withholding so administrative transactions are distinguished from open-market trades.
Are JNJ insiders buying or selling?
Recent JNJ insider activity reads Mixed, buy-heavy: 60 sales and 60 purchases. Awards, gifts, conversions, and tax withholding are listed separately because they do not carry the same signal as open-market trades.
Who is the most active JNJ insider?
WOLK, JOSEPH J is the most active JNJ insider by absolute share movement, with 280,545 shares moving across the filing history. Review the action labels before treating that activity as buying or selling.